Curran Simpson | BiotechTV

top of page

The early part of 2026 is going to be a key time for REGENXBIO's gene therapies, with an FDA decision date scheduled for Hunter's Syndrome and a pivotal trial readout in DMD

CEO Curran Simpson describes REGENXBIO's expertise in AAV, and walks us through the company's programs. Coverage brought to you by

Company News

5 days ago

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Evaluate is a trusted provider of forecasting and commercial intelligence to the pharmaceutical industry. With a combination of gold standard data sources and deep pharma expertise, Evaluate helps clients make the right portfolio decisions to drive growth.

Evaluate's solutions provide a complete, dynamic view of development risk and commercial return across the full clinical lifecycle, underpinned by consensus forecasts to 2032, pipelines, deals and more. A consulting and analytics team is on always hand to help clients address unique clinical and commercial challenges.

Learn more about Evaluate

bottom of page

The early part of 2026 is going to be a key time for REGENXBIO's gene therapies, with an FDA decision date scheduled for Hunter's Syndrome and a pivotal trial readout in DMD

Follow BiotechTV

Sponsors

Sponsor Spotlight